primari
object
random
control
challeng
studi
investig
effect
ampicillin
ultrasonograph
us
lung
consolid
experiment
challeng
pasteurella
multocida
prewean
dairi
calv
secondari
object
determin
whether
ampicillin
affect
respiratori
score
gross
consolid
detect
p
multocida
lung
tissu
postmortem
exam
pme
holstein
bull
calv
n
transport
univers
wisconsinmadison
school
veterinari
medicin
isol
facil
mean
age
acclim
period
calv
inocul
intratrach
cfu
ampicillinsensit
p
multocida
lung
us
respiratori
score
perform
h
postchalleng
us
daili
respiratori
score
twice
daili
calv
random
receiv
ampicillin
n
treatment
tx
mgkg
im
daili
placebo
n
control
con
salin
equal
volum
im
daili
cm
lung
consolid
observ
h
elaps
sinc
challeng
lung
lesion
cm
consid
posit
consolid
calv
respiratori
score
posit
categori
base
wisconsin
respiratori
health
score
chart
area
curv
auc
calcul
us
score
respiratori
score
proxi
time
consolid
clinic
respiratori
diseas
respect
gross
lung
lesion
pathogen
quantifi
follow
pme
time
first
treatment
consolid
develop
calv
tx
n
con
n
tx
con
calv
posit
respiratori
score
tx
calv
significantli
lower
median
interquartil
rang
given
parenthes
auc
us
score
tx
con
wherea
mean
auc
respiratori
score
differ
group
tx
con
tx
con
calv
lung
consolid
tx
con
calv
clinic
respiratori
diseas
pme
median
consolid
tx
con
calv
lung
cultur
posit
p
multocida
tx
con
calv
lung
health
benefit
ampicillin
therapi
benefit
shortliv
treatment
failur
might
due
incomplet
resolut
initi
lung
infect
futur
studi
need
optim
tx
strategi
improv
longterm
lung
health
respiratori
diseas
adult
dairi
cattl
report
infrequ
produc
usda
howev
condemn
dairi
cull
cow
due
pneumonia
make
second
lead
caus
postmortem
condemn
white
moor
accord
latest
nation
anim
health
monitor
system
dairi
studi
adult
cow
producerdiagnos
respiratori
diseas
treat
antibiot
vast
major
receiv
usda
interestingli
nearli
affect
cow
remov
herd
despit
antibiot
therapi
case
usda
treatment
failur
due
late
detect
incorrect
antibiot
dose
durat
spectrum
bacteri
resist
potenti
reason
poor
outcom
therapi
purul
nasal
discharg
cough
poor
milk
product
weight
loss
usual
lead
diagnosi
chronic
suppur
bronchopneumonia
howev
respons
treatment
rare
assess
quantit
barrett
scott
auscult
fail
identifi
natur
extent
lung
patholog
adult
cattl
chronic
suppur
pneumonia
wherea
ultrasonograph
us
examin
chest
provid
critic
inform
diagnosi
suppur
pulmonari
diseas
formul
prognosi
scott
bacteria
trueperella
pyogen
commonli
found
within
lung
affect
cattl
potenti
wall
inaccess
antibiot
barrett
result
anim
may
respond
poorli
treatment
suffer
chronic
weight
loss
even
die
result
acut
exacerb
respiratori
diseas
barrett
recent
report
favor
respons
longterm
penicillin
therapi
cow
us
evid
suppur
bronchopneumonia
challeng
idea
cattl
chronic
pneumonia
respond
poorli
treatment
scott
current
rel
antibiot
treatment
option
exist
lactat
dairi
cattl
respiratori
diseas
although
macrolid
phenicol
fluoroquinolon
product
commonli
use
treat
nonlact
cattl
none
approv
use
lactat
dairi
cattl
femal
cattl
mo
age
older
convers
ampicillin
trihydr
polyflex
boehring
ingelheim
duluth
ga
fda
approv
treatment
respiratori
diseas
lactat
dairi
cattl
ampicillin
provid
bactericid
activ
gramposit
gramneg
organ
specif
pasteurella
multocida
common
bacteri
agent
associ
bovin
respiratori
diseas
brd
dabo
et
al
aim
studi
improv
understand
bovin
lung
respons
antibiot
therapi
bacteri
respiratori
infect
assess
lung
consolid
via
us
gross
postmortem
examin
pme
clinic
respons
use
respiratori
score
ultrasound
evalu
extent
lung
consolid
reliabl
method
confirm
bronchopneumonia
calv
without
clinic
sign
brd
ollivett
buczinski
addit
aim
studi
determin
whether
antibiot
treatment
would
alter
likelihood
isol
bacteri
pathogen
lung
tissu
pme
ampicillin
trihydr
select
fda
approv
statu
frequent
use
lactat
dairi
cattl
respiratori
diseas
given
rel
low
rate
clinic
respiratori
diseas
lactat
cattl
challeng
model
use
calv
could
provid
inform
regard
lung
respons
therapi
effici
costeffect
manner
field
trial
lactat
cattl
first
object
investig
effect
ampicillin
us
lung
consolid
experiment
challeng
p
multocida
prewean
dairi
calv
secondari
object
determin
whether
ampicillin
affect
respiratori
score
gross
consolid
detect
p
multocida
lung
tissu
pme
hypothes
treatment
ampicillin
would
decreas
proport
calv
develop
sever
lung
consolid
clinic
respiratori
diseas
experiment
infect
compar
control
addit
treat
group
would
less
gross
consolid
fewer
calv
p
multocida
isol
lung
tissu
pme
compar
control
random
control
studi
complet
juli
august
univers
wisconsin
livestock
laboratori
madison
wisconsin
research
project
approv
univers
wisconsin
institut
anim
care
use
committe
protocol
institut
biosafeti
committe
protocol
fortyf
holstein
bull
calv
born
may
may
rais
individu
calf
hutch
commerci
dairi
southeast
wisconsin
calv
receiv
colostrum
colostrum
replac
follow
birth
blood
drawn
serum
total
protein
measur
via
digit
refractometri
h
age
addit
calv
administ
intranas
respiratori
vaccin
inforc
zoeti
kalamazoo
mi
first
h
life
respiratori
score
mcguirk
peek
lung
us
ollivett
buczinski
perform
weekli
week
transport
research
facil
monitor
respiratori
diseas
clinic
respiratori
score
assign
point
follow
categori
rectal
temperatur
nasal
discharg
cough
ocular
discharg
ear
posit
mcguirk
peek
calv
respiratori
score
categori
consid
posit
clinic
fever
defin
temperatur
score
high
fever
temperatur
regard
lung
us
left
right
lung
field
scan
imag
interpret
use
us
lung
score
previous
describ
ollivett
buczinski
us
score
indic
normal
aerat
lung
consolid
minim
comettail
artifact
ollivett
buczinski
score
signifi
diffus
comettail
artifact
without
consolid
ollivett
buczinski
cm
lung
consolid
develop
us
score
assign
ollivett
buczinski
score
repres
complet
consolid
lung
lobe
respect
ollivett
buczinski
calv
receiv
score
correspond
signific
lesion
depth
dorsaltoventr
extent
consolid
lung
measur
within
intercost
space
use
grid
line
us
screen
ibex
pro
e
medic
loveland
co
purpos
studi
normal
lung
us
score
cm
consolid
score
sever
consolid
score
calv
remain
respiratori
score
neg
normal
lung
us
receiv
treatment
diarrhea
respiratori
diseas
thu
meet
inclus
criteria
studi
calv
n
transport
sourc
farm
univers
isol
facil
mean
standard
deviat
sd
age
upon
arriv
calv
weigh
deep
nasopharyng
swab
dnp
collect
respiratori
pathogen
analysi
one
swab
place
viral
transport
medium
ami
bacteri
transport
medium
dnp
swab
submit
wisconsin
veterinari
diagnost
laboratori
wvdl
madison
bovin
complet
respiratori
panel
calv
n
identifi
uniqu
numer
plastic
ear
tag
randomli
alloc
pen
pen
pen
use
random
number
gener
pen
locat
singl
room
concret
wall
slat
floor
pen
well
adjac
pen
divid
solid
partit
prevent
physic
contact
calv
differ
pen
pen
clean
disinfect
twice
daili
univers
staff
calv
fed
milk
replac
land
olak
amplifi
max
oz
powder
quart
water
arden
hill
mn
everi
h
via
milk
bar
pen
equip
automat
water
fresh
freechoic
textur
calf
starter
vita
plu
crude
protein
madison
wi
provid
daili
visual
timelin
data
collect
portray
figur
acclim
period
calv
enrol
challeng
studi
enrol
criteria
includ
temperatur
normal
lung
us
neg
respiratori
score
enrol
took
place
day
challeng
baselin
time
second
set
dnp
collect
calf
calv
met
enrol
criteria
one
calf
pen
calv
pen
meet
enrol
criteria
keep
pen
number
similar
prevent
addit
stress
rearrang
social
group
number
drawn
hat
randomli
elimin
addit
calf
pen
final
pen
composit
includ
pen
one
pen
challeng
solut
develop
use
wildtyp
strain
p
multocida
obtain
wvdl
strain
p
multocida
use
studi
consid
sensit
mic
ampicillin
figur
challeng
studi
timelin
triangl
repres
time
deep
nasopharyng
swab
collect
first
swab
collect
upon
arriv
livestock
laboratori
challeng
second
set
swab
collect
challeng
third
set
collect
time
calf
first
treatment
occur
least
cm
consolid
observ
h
elaps
sinc
challeng
denot
asterisk
fourth
set
swab
collect
follow
final
examin
euthanasia
us
lung
ultrasound
cr
clinic
respiratori
score
individu
tube
contain
ml
brain
heart
infus
broth
inocul
p
multocida
tube
incub
h
growth
occur
tube
centrifug
pellet
bacteri
cell
pellet
tube
resuspend
ml
pb
fetal
bovin
serum
fb
creat
solut
contain
p
multocida
cfuml
ml
pb
fb
total
dose
cfu
calf
fb
prepar
ad
ml
fb
ml
pb
one
tube
later
plate
confirm
cfuml
inocula
inocul
dose
extend
ml
ad
ml
pb
challeng
day
calv
sedat
mgkg
xylazin
iv
anas
inject
mgml
akorn
anim
health
lake
forest
il
rigid
multifunct
digit
endoscop
ivetscop
sec
repro
inc
quebec
canada
use
visual
oropharynx
arytenoid
subsequ
passag
steril
equin
infus
pipett
arytenoid
trachea
equin
infus
pipett
continent
plastic
distribut
valley
vet
suppli
marysvil
ks
pipett
advanc
level
thorac
inlet
proxim
tracheal
bifurc
suspens
cfu
ampicillinsensit
p
multocida
instil
immedi
follow
instil
inoculum
calv
stimul
take
deep
breath
partial
occlud
nare
lung
us
respiratori
score
perform
h
postchalleng
us
daili
respiratori
score
twice
daili
total
calv
underw
us
exam
respiratori
score
respiratori
score
perform
blind
research
assist
lung
us
decreas
interobserv
variabl
scorer
train
person
ch
ultrasonographi
perform
experienc
oper
ch
sr
observ
measur
spoken
record
ipad
research
assist
ultrasonograph
ch
sr
blind
treatment
group
throughout
data
collect
calv
random
receiv
mgml
ampicillin
n
treatment
tx
mgkg
im
daili
placebo
n
control
con
steril
salin
equal
volum
im
daili
use
random
number
gener
treatment
began
least
cm
consolid
observ
h
elaps
sinc
challeng
third
set
dnp
collect
treatment
follow
final
examin
fourth
set
dnp
collect
calv
euthan
intraven
overdos
lb
barbitur
beuthanasiad
special
merck
anim
health
kenilworth
nj
sixteen
calv
euthan
challeng
remain
euthan
challeng
calv
chosen
euthanasia
base
order
inocul
pme
perform
immedi
follow
euthanasia
digit
photograph
taken
lung
situ
calv
left
later
recumb
lung
heart
remov
en
bloc
thorac
caviti
clean
lesion
note
digit
photo
taken
right
left
lung
later
perspect
later
morphometr
analysi
individu
lung
lobe
heart
weight
obtain
lungtoheart
weight
ratio
use
indic
degre
inflammatori
infiltr
lung
assumpt
lung
less
consolid
therefor
fewer
infiltr
would
weigh
less
smaller
lungtoheart
ratio
lung
sever
infiltr
j
l
caswel
univers
guelph
ontario
ca
person
commun
ratio
calcul
sum
individu
lung
weight
divid
heart
weight
repres
tissu
sampl
collect
bacteriolog
bovin
respiratori
diseas
complet
panel
perform
wvdl
set
dnp
lung
tissu
sampl
pcr
test
includ
panel
bovin
viral
diarrhea
viru
infecti
bovin
rhinotrach
viru
bovin
syncyti
viru
bovin
respiratori
coronaviru
bocv
bibersteinia
trehalosi
histophilu
somni
mannheimia
haemolytica
pasteurella
multocida
mycoplasma
bovi
bacteri
cultur
antimicrobi
suscept
also
perform
realtim
pcr
provid
rel
valu
cycl
threshold
ct
indic
amount
target
nucleic
acid
sampl
cycl
threshold
invers
proport
amount
target
present
sampl
ie
lower
ct
valu
indic
nucleic
acid
calv
consid
pcr
posit
aforement
pathogen
ct
valu
cutoff
determin
wvdl
morphometr
analysi
use
quantifi
percent
surfac
area
consolid
lung
gross
pme
use
comput
program
imagej
laboratori
optic
comput
instrument
madison
wi
lung
lobe
outlin
determin
total
surfac
area
particular
lung
area
consolid
outlin
sum
ascertain
total
surfac
area
consolid
combin
surfac
area
consolid
lung
divid
total
surfac
area
lung
determin
overal
percent
consolid
experiment
unit
individu
calf
base
previou
work
ollivett
clinic
experi
base
sampl
size
calcul
assumpt
challeng
untreat
con
calv
challeng
antibiotictr
tx
calv
would
affect
sever
lung
consolid
plan
enrol
tx
calv
everi
con
calf
would
result
approxim
tx
con
calv
standard
statist
packag
use
analys
sa
v
sa
institut
inc
cari
nc
graph
us
score
yaxi
time
point
xaxi
area
curv
auc
determin
calf
sum
trapezoid
area
success
time
point
individu
auc
summar
group
report
median
interquartil
rang
given
parenthes
graph
total
respiratori
score
yaxi
time
point
xaxi
approach
taken
calcul
auc
clinic
respiratori
score
continu
variabl
assess
normal
use
shapirowilk
test
variabl
follow
normal
distribut
auc
clinic
respiratori
score
maximum
total
respiratori
score
lungtoheart
weight
ratio
compar
use
student
ttest
measur
central
tendenc
report
mean
sd
grouplevel
comparison
continu
variabl
follow
normal
distribut
evalu
use
wilcoxon
rank
sum
test
measur
central
tendenc
report
median
interquartil
rang
variabl
number
us
exam
consolid
number
us
exam
sever
consolid
auc
us
score
exam
number
first
posit
respiratori
score
follow
challeng
number
posit
respiratori
score
exam
us
exam
number
calv
first
met
treatment
criteria
lung
us
score
first
treatment
total
respiratori
score
first
treatment
number
exam
fever
maximum
total
respiratori
score
percent
consolid
morphometr
analysi
grouplevel
comparison
categor
variabl
assess
conting
tabl
chisquar
analysi
fisher
exact
test
expect
cell
count
signific
set
challeng
calv
n
adequ
passiv
transfer
matern
antibodi
serum
total
protein
gdl
tyler
et
al
surviv
studi
period
twentyeight
calv
develop
least
cm
lung
consolid
within
h
challeng
random
treatment
tx
n
con
n
challeng
model
fail
induc
bronchopneumonia
calv
calv
exclud
analys
ultrasound
score
clinic
respiratori
score
exam
number
time
first
treatment
similar
tx
con
calv
indic
success
random
tabl
p
box
whisker
plot
demonstr
distribut
us
clinic
respiratori
score
cours
studi
period
shown
figur
calv
normal
lung
us
score
challeng
figur
last
treatment
lung
us
score
similar
group
tx
con
p
tx
calv
fewer
exam
consolid
smaller
auc
us
score
compar
con
calv
tabl
p
nearli
calv
develop
sever
consolid
least
tx
con
p
affect
calv
sever
consolid
detect
hour
inocul
tx
con
calv
respect
p
treatment
initi
normal
lung
score
us
score
observ
least
tx
con
calv
respect
p
lung
consolid
recur
latter
half
studi
figur
specif
calv
develop
normal
lung
score
follow
treatment
lung
consolid
recur
tx
con
calv
respect
endpoint
studi
tx
con
calv
normal
lung
score
p
throughout
studi
period
pattern
us
lung
consolid
match
pattern
posit
clinic
respiratori
score
figur
challeng
calv
normal
clinic
respiratori
score
figur
time
first
treatment
tx
con
calv
respect
posit
clinic
respiratori
score
p
howev
posit
clinic
respiratori
score
fever
eventu
develop
least
calv
occur
similarli
group
tabl
p
addit
depress
titud
score
detect
least
tx
con
calv
respect
depress
occur
calv
endpoint
studi
tx
con
calv
normal
clinic
respiratori
score
p
pme
lung
contain
firm
dark
purpl
red
gross
lesion
cranioventr
lung
lobe
figur
purul
exud
commonli
detect
bronchi
bronchiol
fibrin
fibrou
adhes
thorac
bodi
wall
figur
distend
interlobular
septa
edema
fibrin
abscess
variabl
find
mean
lungtoheart
weight
ratio
tx
con
calv
respect
p
median
percent
consolid
tx
con
calv
p
antemortem
cultur
pcr
result
dnp
sampl
describ
tabl
respect
regardless
test
method
antibiot
treatment
associ
pathogen
detect
within
individu
time
point
p
regardless
treatment
group
risk
detect
p
multocida
dnp
least
time
higher
endpoint
studi
compar
prechalleng
sampl
cultur
p
pcr
p
contrast
detect
haemolytica
cultur
pcr
pyogen
cultur
similar
prechalleng
endofstudi
dnp
sampl
p
postmortem
lung
tissu
cultur
pcr
result
describ
figur
boxplot
ultrasound
score
total
respiratori
score
examin
throughout
studi
period
line
within
box
median
ultrasound
score
line
form
bottom
top
box
percentil
respect
interquartil
rang
whisker
repres
minimum
maximum
data
point
fall
within
rang
interquartil
distanc
lower
quartil
upper
quartil
outlier
repres
open
circl
black
arrow
indic
experiment
challeng
use
pasteurella
multocida
occur
area
curv
ultrasound
score
figur
proport
calv
lobar
pneumonia
diagnos
ultrasonograph
score
greater
uss
posit
clinic
respiratori
score
cr
b
throughout
studi
period
exam
perform
day
challeng
h
postchalleng
daili
studi
calv
random
receiv
ampicillin
tx
n
mgkg
im
daili
placebo
con
n
salin
equal
volum
im
daili
cm
lung
consolid
observ
h
elaps
sinc
challeng
calv
challeng
intratrach
cfu
pasteurella
multocida
dark
gray
bar
con
light
gray
bar
tx
although
calv
neg
upon
arriv
day
challeng
bocv
eventu
detect
pcr
dnp
lung
tissu
sampl
tabl
specif
bocv
detect
calv
end
studi
compar
prechalleng
sampl
tabl
p
lung
bocv
isol
pcr
less
frequent
among
tx
calv
compar
con
calv
tabl
p
studi
success
induc
p
multocida
bronchopneumonia
found
earli
antibiot
therapi
affect
sever
lung
consolid
prewean
dairi
calv
also
observ
lung
consolid
recur
pathogen
detect
lung
upper
airway
follow
treatment
even
though
major
calv
clinic
respiratori
diseas
last
antibiot
treatment
end
studi
result
suggest
possibl
mechan
treatment
failur
cattl
failur
complet
cure
bacteri
infect
associ
lung
consolid
challeng
model
use
studi
intend
creat
acut
moder
sever
diseas
patholog
typic
cranioventr
bacteri
bronchopneumonia
consist
gross
report
studi
dabo
et
al
smith
studi
previou
p
multocida
challeng
studi
use
compar
techniqu
found
depress
attitud
gave
littl
evid
sever
lung
consolid
pme
although
rectal
temperatur
respiratori
rate
higher
challeng
anim
inform
provid
littl
indic
extent
patholog
chang
dagleish
et
al
second
compar
challeng
studi
show
percentag
abnorm
lung
surfac
rang
mean
rel
similar
observ
current
studi
reinhold
et
al
isol
p
multocida
princip
bacterium
recov
pneumon
lung
necropsi
consid
indic
causal
relationship
simpl
isol
nasal
swab
griffin
current
studi
combin
bacteriolog
find
dnp
lung
tissu
sampl
support
p
multocida
respons
develop
bacteri
bronchopneumonia
among
studi
calv
pasteurella
multocida
often
isol
nasal
secret
deep
pharyng
swab
young
calv
report
isol
rate
clinic
normal
cattl
high
dabo
et
al
shown
data
clinic
normal
calv
subclin
bronchopneumonia
therefor
isol
rate
pathogen
appar
healthi
cattl
interpret
caution
unless
lung
us
use
confirm
lung
ultrasonograph
healthi
addit
document
clinic
cure
due
antibiot
administr
dedond
apley
certain
level
clinic
spontan
recoveri
expect
due
fulli
compet
success
immun
respons
dedond
apley
must
keep
mind
howev
clinic
spontan
recoveri
equal
bacteriolog
cure
within
parenchyma
lung
result
show
dispar
proport
calv
clinic
respiratori
diseas
end
studi
compar
us
consolid
mean
calv
seemingli
free
clinic
diseas
may
actual
recov
recent
studi
investig
attitud
score
respiratori
diseas
use
lung
us
clinic
respiratori
score
calv
clinic
brd
like
depress
attitud
calv
subclin
brd
cramer
howev
sensit
attitud
score
alon
poor
cramer
studi
highlight
difficulti
use
typic
sick
behavior
depress
attitud
fever
increas
respiratori
rate
alon
diagnos
bronchopneumonia
prewean
dairi
calv
studi
highlight
challeng
identifi
point
treat
antibiot
use
clinic
sign
alon
emphas
fact
respiratori
diseas
develop
shortli
infect
determin
lung
consolid
us
onset
clinic
sign
variabl
recurr
us
lung
lesion
document
studi
might
result
failur
elimin
initi
bacteri
lung
infect
indic
lack
treatment
effect
final
dnp
sampl
lung
tissu
sampl
plausibl
antibiot
therapi
withdrawn
bacteri
replic
resum
ultim
lead
treatment
failur
case
treatment
failur
could
defin
presenc
consolid
lung
viabl
pathogen
diagnos
pme
studi
design
elimin
common
caus
treatment
failur
chronic
case
inappropri
antibiot
spectrum
antibiot
resist
poor
complianc
probabl
suboptim
antibiot
dose
durat
frequenc
administr
contribut
treatment
failur
studi
gener
pauciti
data
regard
optim
durat
antibiot
therapi
brd
human
pneumonia
studi
evalu
antimicrobi
durat
swab
collect
upon
arriv
livestock
laboratori
challeng
swab
collect
challeng
baselin
swab
collect
treatment
least
cm
consolid
observ
h
elaps
sinc
challeng
swab
collect
follow
final
examin
euthanasia
coronaviru
consist
unabl
demonstr
differ
shorter
longer
treatment
durat
apley
shaddock
feldman
human
medicin
emphasi
durat
therapi
driven
need
balanc
therapeut
efficaci
minim
exposur
attempt
curb
develop
antibiot
resist
label
ampicillin
trihydr
indic
dairi
cattl
treat
dose
mgkg
im
everi
h
treatment
continu
anim
becom
afebril
longer
accord
human
literatur
practic
farm
chose
treat
calv
short
durat
abil
continu
treatment
addit
calv
remain
febril
display
sever
clinic
sign
respiratori
diseas
moder
sever
nasal
ocular
discharg
spontan
cough
h
past
last
treatment
posttreat
interv
classic
assum
antibiot
requir
daili
administr
brd
ampicillin
trihydr
apley
none
calv
tx
group
elig
prolong
therapi
base
guidelin
purpos
studi
dose
ampicillin
middl
label
rang
mgkg
use
determin
whether
judici
antibiot
use
would
still
lead
clinic
us
improv
ultim
bacteriolog
cure
timedepend
antibiot
ampicillin
signific
factor
determin
efficaci
length
time
serum
concentr
exceed
mic
given
pathogen
et
al
increas
concentr
drug
severalfold
mic
significantli
increas
rate
microbi
kill
howev
frequent
dose
ensur
adequ
coverag
throughout
period
may
increas
bactericid
activ
et
al
earli
studi
look
bioavail
pharmacokinet
ampicillin
trihydr
healthi
rumin
calv
dose
mgkg
im
reveal
maximum
plasma
concentr
ml
approxim
h
administr
halflif
h
nouw
et
al
extrapol
data
studi
mic
p
multocida
plasma
concentr
ampicillin
would
drop
mic
approxim
h
purpos
studi
assess
pharmacokinet
properti
ampicillin
emphas
research
need
determin
whether
increas
dose
frequenc
ampicillin
administr
could
lead
sustain
lung
health
perhap
use
highest
label
dose
base
durat
therapi
us
resolut
consolid
oppos
clinic
respiratori
sign
would
better
treatment
success
current
time
produc
still
reli
clinic
sign
alon
determin
need
treat
respiratori
diseas
antibiot
use
lung
us
make
treatment
decis
broadli
applic
econom
feasibl
field
set
increas
involv
veterinarian
train
lung
us
addit
academ
pharmaceuticalindustri
research
appropri
dose
regimen
antibiot
use
treat
respiratori
diseas
could
greatli
enhanc
incorpor
lung
us
studi
design
limit
studi
evalu
respiratori
rate
charact
part
clinic
examin
although
signific
increas
respiratori
rate
consist
found
previou
p
multocida
challeng
studi
result
mix
regard
correl
patholog
morpholog
chang
lung
reinhold
et
al
dagleish
et
al
respiratori
rate
analysi
would
subject
popul
calv
given
group
hous
restrain
calv
respiratori
score
handl
calv
increas
activ
level
may
fals
elev
respiratori
rate
respiratori
rate
analysi
would
benefici
taken
outsid
pen
calv
rest
anoth
limit
coronaviru
detect
calv
last
day
studi
dnp
lung
tissu
respiratori
bocv
associ
mild
respiratori
diseas
cough
rhiniti
interstiti
pneumonia
calv
saif
respiratori
coinfect
immunosuppress
potenti
cofactor
enhanc
viru
shed
saif
possibl
studi
calv
may
infect
bocv
shed
viru
detect
level
test
challeng
stress
p
multocida
pneumonia
stimul
increas
shed
viral
particl
aim
studi
improv
understand
bovin
lung
respons
antibiot
therapi
bacteri
respiratori
infect
calf
challeng
model
limit
generaliz
result
pathophysiolog
respiratori
diseas
calv
versu
adult
may
vari
due
differ
immun
respons
pathogen
load
environment
condit
although
result
provid
valuabl
insight
effect
antibiot
treatment
brd
prewean
calv
field
trial
warrant
determin
effect
antibiot
treatment
adult
dairi
cattl
respiratori
diseas
studi
respiratori
diseas
induc
common
respiratori
pathogen
p
multocida
antibiot
treatment
initi
base
presenc
us
lung
consolid
shortterm
benefit
antibiot
treatment
evid
relaps
success
measur
use
lung
us
despit
inconsist
clinic
diseas
result
highlight
disconnect
system
pulmonari
manifest
bacteri
respiratori
diseas
reinforc
need
sensit
diagnost
tool
lung
us
accur
classifi
diseas
regardless
clinic
sign
opportun
exist
use
techniqu
earli
detect
pneumonia
well
defin
recoveri
respiratori
diseas
farm
research
set
futur
clinic
trial
investig
whether
adjust
dose
durat
frequenc
antibiot
administr
may
lead
prolong
sustain
lung
health
therefor
prudent
drug
use
